Anvisa could not give details of what happened due to privacy rules (representation)
Rio de Janeiro:
The Brazilian health regulator announced on Monday that it had suspended clinical trials of a Covid-19 vaccine developed in China after an “adverse incident” involving a voluntary recipient, a blow to one of the most advanced vaccine candidates.
The regulator, Anvisa, said in a statement that it had “decided to stop the clinical trial of the CoronaVac vaccine after a serious adverse event” on October 29.
He said he couldn’t give details of what happened due to privacy regulations, but those incidents included death, life-threatening side effects, severe disability, hospitalization, birth defects and other “clinically significant events”.
(Except for the title, this story was not edited by GalacticGaming staff and is posted from a syndicated feed.)
